International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

  • Published 2009

Abstract

Oncolytic viruses (OV) were first observed in early clinical studies in patients with malignancies where tumour regressions were observed to coincide with viral infections or with live virus vaccinations. Since these early reports, studies using OV have progressed from anecdotal and controlled infections to specifically selecting or genetically modifying viruses for cancer treatment. OV are intended to replicate selectively in tumour tissue and spread, destroying the tissue without causing excessive damage to normal tissues.

Cite this paper

@inproceedings{2009InternationalCO, title={International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use}, author={}, year={2009} }